目的：本研究為探討電腦刀進行立體定位消融放射治療，用於惡性肉瘤肺轉移的治療反應及副 作用。 材料與方法：本研究針對惡性肉瘤患者，分析肺部的轉移病灶至本科接受立體定位消融放射治 療的效果。腫瘤的治療反應透過追蹤的電腦斷層影像，以 2009 年的 RECIST 準則進行評估。毒 副作用則透過定期的門診，以病史詢問和身體檢查的方式追蹤，並根據 RTOG 放射傷害等級標 準進行記錄。各個病人追蹤的時間約一到三年。 結果：三位病人總共有七個肺部轉移病灶。在進行立體定位消融放射治療後的三個月，其中一 個病灶完全消失（complete response），一個病灶部分縮小（partial response）。另外四個病灶維持 穩定的狀態（no change）。只有一個病灶惡化（progressive disease）。此外在本研究期間，沒有 觀察到任何毒性副作用。 結論：對於不適合接受手術的病人，立體定位消融放射治療對於肺部轉移的惡性肉瘤，是一個 可以考慮的替代方案。

Introduction : Based on recently published studies, surgical resection of pulmonary metastatic nodules may improve the prognosis for sarcoma patients. Here, we try to report the safety and efficacy of stereotactic ablative radiotherapy (SABR) as a local treatment for pulmonary metastatic sarcoma. Case report : The present report demonstrated sarcoma patients who were treated for pulmonary metastatic lesions using the CyberKnife® radiosurgery system. There were a total of three patients with seven lesions. In the first 3 months post SABR, one lesion was complete response, another was partial response, 4 lesions was stable disease and only 1 lesion was progressive disease. Overall survival for each patient was 11, 19 and 35 months from lung metastasis diagnosis, respectively. No high grade toxicity was observed at the time of analysis. Discussion : The present report demonstrated that SABR may be an acceptable alternative option for pulmonary metastatic sarcoma in patients in whom surgery is contraindicated. However, more patients are required for statistical analysis.